These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Disseminated malignant melanoma: response to treatment by massive dosage of a cytotoxic agent combined with autogenous marrow replacement. WESTBURY G; HUMBLE JG; NEWTON KA; SKINNER ME; PEGG DE Lancet; 1959 May; 1(7080):968-9. PubMed ID: 13655649 [No Abstract] [Full Text] [Related]
5. Nitrogen and phenylalanine mustard. Use in women with intrauterine cancer. DIDDLE AW; WATTS G; WATTS J; JENKINS HH Am J Obstet Gynecol; 1962 Feb; 83():490-3. PubMed ID: 13886225 [No Abstract] [Full Text] [Related]
6. [A case of malignant melanoma of the leg treated by isolated perfusion of nitrogen mustard]. MANIZADE D; SALEPCIOGLU A; AKTAN K Turk Tip Cemiy Mecm; 1960 Nov; 26():564-9. PubMed ID: 13766186 [No Abstract] [Full Text] [Related]
7. The treatment of malignant melanoma by perfusion techniques. IRVINE WT; NOON CF Proc R Soc Med; 1961 Jun; 54(6):483-5. PubMed ID: 13717903 [No Abstract] [Full Text] [Related]
8. Massive nitrogen mustard therapy in Hodgkin's disease with protection of bone marrow by tourniquets. CONRAD ME; CROSBY WH Blood; 1960 Aug; 16():1089-103. PubMed ID: 13811574 [No Abstract] [Full Text] [Related]
9. Further observations on the efficacy of phenylalanine mustards against mouse melanoma. LUCK JM Cancer Res; 1961 Feb; 21():262-4. PubMed ID: 13764029 [No Abstract] [Full Text] [Related]
10. Chemotherapy of melanoma of the extremities by isolated perfusion. CREECH O; KREMENTZ ET; RYAN RF Cancer Chemother Rep; 1962 Feb; 16():579-81. PubMed ID: 13882088 [No Abstract] [Full Text] [Related]
11. Studies of phenylalanine nitrogen mustard (CB 3025) in metastatic malignant melanoma of man. HOLLAND JF; REGELSON W Ann N Y Acad Sci; 1958 Apr; 68(3):1122-5. PubMed ID: 13627764 [No Abstract] [Full Text] [Related]
12. Protective action of autologous marrow against nitrogen mustard toxicity. BLACK MM; SPEER FD; STONE ML Ann Intern Med; 1959 Sep; 51():517-25. PubMed ID: 13801160 [No Abstract] [Full Text] [Related]
13. Contributions to the treatment of cancer of the head and neck. Nitrogen mustard toxicity and bone marrow infusion. CLIFT RA East Afr Med J; 1961 Nov; 38():500-2. PubMed ID: 13879952 [No Abstract] [Full Text] [Related]
14. Bone marrow protection as a potential aid to chemotherapy. AMBRUS CM; BACK N; AMBRUS JL Acta Unio Int Contra Cancrum; 1960; 16():540-1. PubMed ID: 13793133 [No Abstract] [Full Text] [Related]
15. [A case of prolonged remission of lymphosarcomatosis after sarcolysin and roentgen-ray therapy]. KRASOVSKII II; IAKOVLEV AM Vopr Onkol; 1960; 6(11)():84-6. PubMed ID: 13754023 [No Abstract] [Full Text] [Related]
16. Treatment of disseminated melanoma by systemic melphalan, methotrexate and autogenous bone marrow transplants. Experience with 114 patients. Ariel IM; Pack GT Cancer; 1967 Jan; 20(1):77-85. PubMed ID: 5334533 [No Abstract] [Full Text] [Related]
17. [Bone-marrow transplantation in patients with bone-marrow depression. Aplastic anemia after nitrogen mustard therapy]. HEYL T S Afr Med J; 1961 Jul; 35():604-7. PubMed ID: 13714064 [No Abstract] [Full Text] [Related]
18. Bone marrow protection in mechlorethamine (nitrogen mustard) therapy. MILLER DG; LAWRENCE W Arch Surg; 1962 Sep; 85():430-41. PubMed ID: 14473972 [No Abstract] [Full Text] [Related]
19. Treatment of melanoma by isolation-perfusion technique. CREECH O; RYAN RF; KREMENTZ ET J Am Med Assoc; 1959 Jan; 169(4):339-43. PubMed ID: 13610669 [No Abstract] [Full Text] [Related]